1. Malfunctioning CD106-positive, short-term hematopoietic stem cells trigger diabetic neuropathy in mice by cell fusion
- Author
-
Akane Yamada, Hiroshi Maegawa, Itsuko Miyazawa, Hideto Kojima, Tomoya Terashima, Natsuko Ohashi, Takahiko Nakagawa, Yuki Nakae, Yutaka Eguchi, Junko Okano, Yoshihisa Suzuki, Kazunori Fujino, and Miwako Katagi
- Subjects
0301 basic medicine ,Diabetic neuropathy ,QH301-705.5 ,Medicine (miscellaneous) ,Vascular Cell Adhesion Molecule-1 ,Cell Communication ,General Biochemistry, Genetics and Molecular Biology ,Article ,Diabetes Mellitus, Experimental ,Cell Fusion ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Diabetic Neuropathies ,Diabetes complications ,medicine ,Animals ,Biology (General) ,Pathological ,Cells, Cultured ,Proinsulin ,Bone Marrow Transplantation ,Cell fusion ,business.industry ,Chronic inflammation ,medicine.disease ,Hematopoietic Stem Cells ,Transplantation ,Mice, Inbred C57BL ,Haematopoiesis ,030104 developmental biology ,030220 oncology & carcinogenesis ,Hyperglycemia ,Cancer research ,Tumor necrosis factor alpha ,Stem cell ,General Agricultural and Biological Sciences ,business - Abstract
Diabetic neuropathy is an incurable disease. We previously identified a mechanism by which aberrant bone marrow-derived cells (BMDCs) pathologically expressing proinsulin/TNF-α fuse with residential neurons to impair neuronal function. Here, we show that CD106-positive cells represent a significant fraction of short-term hematopoietic stem cells (ST-HSCs) that contribute to the development of diabetic neuropathy in mice. The important role for these cells is supported by the fact that transplantation of either whole HSCs or CD106-positive ST-HSCs from diabetic mice to non-diabetic mice produces diabetic neuronal dysfunction in the recipient mice via cell fusion. Furthermore, we show that transient episodic hyperglycemia produced by glucose injections leads to abnormal fusion of pathological ST-HSCs with residential neurons, reproducing neuropathy in nondiabetic mice. In conclusion, we have identified hyperglycemia-induced aberrant CD106-positive ST-HSCs underlie the development of diabetic neuropathy. Aberrant CD106-positive ST-HSCs constitute a novel therapeutic target for the treatment of diabetic neuropathy., Katagi et al. show that abnormal bone marrow-derived cells originated from hematopoietic stem cells (CD106-positive short-term HSCs) aberrantly fuse with neurons to develop diabetic neuropathy. This study suggests that the pathological abnormality is memorized in the bone marrow and that it cannot be erased by conventional therapy.
- Published
- 2021